bioRxivImmunology
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
D. C. Palmer, B. R. Webber, Y. Patel, M. J. Johnson, C. M. Kariya, W. S. Lahr, M. R. Parkhurst, J. J. Gartner, T. D. Prickett, F. J. Lowery, R. J. Kishton, D. Gurusamy, Z. Franco, S. K. Vodnala, M. D. Diers, N. K. Wolf, N. J. Slipek, D. H. McKenna, D. Sumstad, L. Viney, T. Henley, T. Burckstummer, O. Baker, Y. Hu, C. Yan, , N. P. Restifo
Abstract
While neoantigen-specific tumor infiltrating lymphocytes (TIL) can be derived from in antigen-expressing tumors, their adoptive transfer fails to consistently elicit durable tumor regression. There has been much focus on the role of activation/exhaustion markers such as PD1, CD39 and TOX in TIL senescence. We found these markers were inversely expressed to Cytokine-Induced SH2 protein (CISH), a negative regulator of TCR signaling and tumor immunity in mice. To evaluate the physiological role of CISH in human TIL we developed a high-efficiency CRIPSR-based method to knock out CISH in fully mature TIL. CISH KO resulted in increased T cell receptor (TCR) avidity, tumor cytolysis and neoantigen recognition. CISH expression in the tumor resections correlated with TIL inactivity against p53 hotspot mutations and CISH KO in TIL unmasked reactivity against these universal neoantigens. While CISH KO resulted in T cell hyperactivation and expansion it did not alter maturation, perhaps by preferential PLC{gamma}-1 and not AKT inhibition. Lastly, CISH KO in T cells increased PD1 expression and the adoptive transfer of Cish KO T cells synergistically combines with PD1 antibody blockade resulting in durable tumor regression and survival in a preclinical animal model. These data offer new insights into the regulation of neoantigen recognition, expression of activation/exhaustion markers, and functional/maturation signals in tumor-specific T cells.
- organism: human
- assay: CITE-seq
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression
E. Arthofer, K. Chakraborty, … T. Henley·bioRxiv·Aug 17, 2021
- CISH, a novel intracellular immune checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
Florencia Cano, Alberto Bravo‐Blas, … Tom Henley·bioRxiv·Apr 26, 2025
- Mechanistic modeling predicts efficacy of CISH knockout in tumor-infiltrating lymphocytes with synergistic gene editing
Nikolaos Memmos, Kamran Kaveh, … David J. Odde·Physical BiologyPeer-reviewed·Feb 17, 2026
- Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
P.-L. Bernard, R. Delconte, … G. Guittard·bioRxiv·Mar 16, 2021
- Pik3ip1/TrIP Regulation of PI3K Restricts CD8 T Cell Anti-Tumor Immunity
Benjamin Murter, Larry Kane·bioRxiv·Jul 10, 2025
- Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
Thomas Fabre, Eleanore Hendrickson, … Alex Barron·bioRxiv·Sep 26, 2025